193 related articles for article (PubMed ID: 11533610)
21. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
Smollich M; Götte M; Yip GW; Yong ES; Kersting C; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2007 Dec; 106(3):361-9. PubMed ID: 17295044
[TBL] [Abstract][Full Text] [Related]
22. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
23. Distribution of endothelin-converting enzyme-1 and neutral endopeptidase in human endometrium.
Iwase A; Ando H; Nagasaka T; Goto M; Harata T; Kikkawa F
J Histochem Cytochem; 2007 Dec; 55(12):1229-35. PubMed ID: 17712175
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
[TBL] [Abstract][Full Text] [Related]
25. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
[TBL] [Abstract][Full Text] [Related]
26. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney.
Russell FD; Coppell AL; Davenport AP
Biochem Pharmacol; 1998 Mar; 55(5):697-701. PubMed ID: 9515580
[TBL] [Abstract][Full Text] [Related]
27. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
Kalk P; Sharkovska Y; Kashina E; von Websky K; Relle K; Pfab T; Alter M; Guillaume P; Provost D; Hoffmann K; Fischer Y; Hocher B
Hypertension; 2011 Apr; 57(4):755-63. PubMed ID: 21339476
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme.
Nelissen J; Lemkens P; Sann H; Bindl M; Bassissi F; Jasserand D; De Mey JG; Janssen BJ
Life Sci; 2012 Oct; 91(13-14):587-92. PubMed ID: 22365954
[TBL] [Abstract][Full Text] [Related]
29. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme.
Woods M; Mitchell JA; Wood EG; Barker S; Walcot NR; Rees GM; Warner TD
Mol Pharmacol; 1999 May; 55(5):902-9. PubMed ID: 10220569
[TBL] [Abstract][Full Text] [Related]
30. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
Dickstein K; De Voogd HJ; Miric MP; Willenbrock R; Mitrovic V; Pacher R; Koopman PA
Am J Cardiol; 2004 Jul; 94(2):237-9. PubMed ID: 15246912
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
[TBL] [Abstract][Full Text] [Related]
32. Modulation of endothelin production and metabolism in guinea-pig tracheal epithelial cells by peptidase inhibitors.
Yang Q; Battistini B; D'Orléans-Juste P; Jeng AY; Sirois P
Am J Respir Crit Care Med; 1997 Jun; 155(6):1884-9. PubMed ID: 9196090
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
[TBL] [Abstract][Full Text] [Related]
34. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kuruppu S; Rajapakse NW; Smith AI
Pflugers Arch; 2013 Jul; 465(7):929-34. PubMed ID: 23328864
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
Jeng AY; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Trapani AJ
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S36-9. PubMed ID: 11078330
[TBL] [Abstract][Full Text] [Related]
36. Mutagenesis of Glu403 to Cys in rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked homodimer: analogy with endothelin-converting enzyme.
Hoang MV; Sansom CE; Turner AJ
Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):925-9. PubMed ID: 9581575
[TBL] [Abstract][Full Text] [Related]
37. Endothelin-converting enzyme inhibitors: current status and perspectives.
Löffler BM
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
[TBL] [Abstract][Full Text] [Related]
38. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of enzymes regulating the activity of endothelin-1 in the lower segment of the human amnion during labor.
Kotani T; Iwase A; Tsuda H; Mano Y; Yamamoto E; Nakano T; Hasegawa Y; Li H; Sumigama S; Itakura A; Kikkawa F
Biol Reprod; 2013 Sep; 89(3):52. PubMed ID: 23863409
[TBL] [Abstract][Full Text] [Related]
40. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats.
Pham D; Jeng AY; Escher E; Sirois P; Battistini B
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S362-6. PubMed ID: 11078421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
